Zogenix Inc., a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, yesterday reported clinical data from its phase 4 open-label, multicenter study of SUMAVEL® DosePro ® Needle-free Delivery System for the treatment of migraines.
The company demonstrated the clinical data in two poster presentations at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Honolulu, Hawaii.
“The clinical findings of this phase 4 study indicate that patients showed a greater Overall Satisfaction with subcutaneous sumatriptan delivered by SUMAVEL DosePro than their current triptan therapy, which was predominantly oral dosage forms. SUMAVEL DosePro improves upon traditional needle-based sumatriptan injection therapy by providing convenience and ease of use in a needle-free delivery system, and may be a useful therapeutic option when rapid onset of efficacy is important in relieving migraine pain and symptoms,” Stephen J. Farr, Ph.D., president and chief operating officer of Zogenix stated in the press release.
John F. Rothrock, M.D., director of the University of Alabama School of Medicine Headache Treatment and Research Program and co-author of the phase 4 study, said the results demonstrate that SUMAVEL DosePro showed an increased rate of lasting relief from migraine symptoms.
“Coupled with the ease of use and rapid onset of action, needle-free SUMAVEL DosePro should be viewed as an attractive addition to the toolbox of migraine therapeutics for patients treating their migraines of moderate to severe intensity,” Dr. Rothrock stated.
The first poster presentation reported on treatment satisfaction, while the second poster presentation reported on the efficacy and tolerability of SUMAVEL DosePro among current triptan users over multiple migraine attacks.
Zogenix and its co-promotion partner Astellas Pharma US, Inc. launched SUMAVEL DosePro in the United States in January 2010.
For more information visit www.zogenix.com
Let us hear your thoughts below:
